Dec 4, 2025 05:27AM Wells Fargo Starts Maze Therapeutics (MAZE) at Overweight

Nov 13, 2025 04:06PM Raymond James Starts Maze Therapeutics (MAZE) at Outperform

Nov 6, 2025 07:01AM Maze Therapeutics presents drug data at kidney conference

Oct 17, 2025 04:20PM Maze Therapeutics (MAZE) files for 9.23M share offering by selling stockholders

Oct 3, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Maze Therapeutics (MAZE)

Sep 15, 2025 07:29AM Maze Therapeutics (MAZE) PT Raised to $50 at H.C. Wainwright

Sep 15, 2025 07:25AM Maze Therapeutics (MAZE) PT Raised to $34 at Guggenheim

Sep 12, 2025 07:32AM Maze Therapeutics (MAZE) PT Raised to $50 at H.C. Wainwright

Sep 11, 2025 03:56PM Maze Therapeutics (MAZE) PT Raised to $37 at BTIG

Sep 11, 2025 03:45PM Maze Therapeutics (MAZE) PT Raised to $34 at Leerink Partners

Sep 2, 2025 06:37AM BTIG Starts Maze Therapeutics (MAZE) at Buy

Aug 12, 2025 04:55PM Maze Therapeutics, Inc. (MAZE) Misses Q2 EPS by 15c

Jul 23, 2025 07:48AM H.C. Wainwright Starts Maze Therapeutics (MAZE) at Buy

May 15, 2025 05:23PM Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss of $1.15

Feb 25, 2025 06:29AM Leerink Partners Starts Maze Therapeutics (MAZE) at Outperform

Feb 25, 2025 05:30AM TD Cowen Starts Maze Therapeutics (MAZE) at Buy

Feb 25, 2025 12:59AM Guggenheim Starts Maze Therapeutics (MAZE) at Buy

Feb 25, 2025 12:58AM JPMorgan Starts Maze Therapeutics (MAZE) at Overweight

Feb 7, 2025 08:01AM Maze Therapeutics (MAZE) Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

Jan 31, 2025 12:21PM Maze Therapeutics (MAZE) Opens At $16.12, IPO Priced At $16

Jan 27, 2025 06:10AM Maze Therapeutics (MAZE) Files for 7.8M Share IPO at $15-$17/sh